SHERESHEVSKIY-TERNER SINDROMIDAGI ASORATLARNING RIVOJLANISHI VA PROGNOZLANISHIDA MOLEKULYAR GENETIK BELGILAR
##article.subject##:
xromosoma, past bo’lik, nuqsonlar##article.abstract##
Shereshevskiy-Terner sindromi — fenotipik ayollarda X xromosomalardan birining toʻliq yoki qisman yoʻqolishi natijasida kelib chiqadigan xromosomal buzilish. Klinik xususiyatlari kariotipga bog'liq bo'lib, odatda tuxumdonlar disgeneziyasi, yurak nuqsonlari va neyrokognitiv zaiflik, past bo’ylik, gipergonadotrop gipogonadizmni o'z ichiga oladi.
Библиографические ссылки
Al Alwan I.M, Amir I. et al. Turner Syndrome Genotype and phenotype and their effect on presenting features and timing of Diagnosis. Int J Health Sci (Qassim). 2014; 8(2):195-202. doi: 10.12816/0006086.
Aversa T., Messina M., Mazzanti L. et al. The association with Turner syndrome significantly affects the course of Hashimoto’s thyroiditis in children, irrespective of karyotype. Endocrine. 2015; 50: 777–782. doi: 10.1007/s12020-014-0513-6.
Aversa T., Salerno M., Radetti G. et al. Peculiarities of presentation and evolution over time of Hashimoto’s thyroiditis in children and adolescents with Down’s syndrome. Hormones (Athens). 2015а; 14: 410–416. doi: 10.14310/horm.2002.1574.
Baguet J. Douchin S. Pierre H. et al. Structural and functional abnormalities of large arteries in Turner syndrome. Heart. 2005; 91: 1442–1446.
Bakalov V., Axelrod L., Baron J. et al. Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab. 2003; 88: 5717–5722. doi: 10.1210/jc.2003-030913.
Bakalov V., Bondy C. Fracture risk and bone mineral density in Turner syndrome. Rev Endocr Metab Disord. 2008; 9: 145–151. doi: 10.1007/s11154-008-9076-2.
Bianco B., Verreschi I., Oliveira K. et al. Analysis of vitamin D receptor gene (VDR) polymorphisms in Turner syndrome patients. Gynecol Endocrinol. 2012; 28(4): 326-329. doi: 10.3109/09513590.2011.631630.
Bondy C. Congenital cardiovascular disease in Turner syndrome. Congenit Heart Dis. 2008; 3(1): 2-15. doi: 10.1111/j.1747-0803.2007.00163.x.
Calcaterra V., Gamba G., Montani N. et al. Thrombophilic screening in Turner syndrome. J Endocrinol Invest. 2011 Oct; 34((9)): 676–679.
Calcaterra V., Larizza D., De Giuseppe R. et al. Diet and Lifestyle Role in Homocysteine Metabolism in Turner Syndrome. Med Princ Pract. 2019; 28(1): 48-55. doi: 10.1159/000494138.
Chiarito M., Brunetti G., D’Amato G., Faienza M. Monitoring and maintaining bone health in patients with Turner syndrome. Expert Rev Endocrinol Metab. 2020; 15: 431–438. doi: 10.1080/17446651.2020.1834846.
Chiarito M., Piacente L., Chaoul N. et al. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome. J Endocrinol Invest. 2022; 45(6): 1255-1263. doi: 10.1007/s40618-022-01760-3.
Dudmam N. An alternative view of homocysteine. Lancet. 1999; 8: 65–68.
Faienza M., Ventura A., Colucci S. et al. Bone fragility in Turner syndrome: mechanisms and prevention strategies. Front Endocrinol. 2016; 7: 34. doi: 10.3389/fendo.2016.00034.
Gasperini B., Visconti V., Ciccacci C. et al. Role of the Vitamin D Receptor (VDR) in the Pathogenesis of Osteoporosis: A Genetic, Epigenetic and Molecular Pilot Study. Genes (Basel). 2023; 14(3): 542. doi: 10.3390/genes14030542.
Goyette P., Summer J., Milos R. et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994; 7: 195–200.
Holroyd C., Davies J., Taylor P. et al. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos Int. 2010; 21: 2093–2099. doi: 10.1007/s00198-010-1170-0.
Kaldmäe M., Zilmer M. Viigimaa M, et al. Cardiovascular disease risk factors in homeless people. Ups J Med Sci. 2011; 116: 200–2007.
Kim H., Gottliebson W., Hor K. et al. Cardiovascular anomalies in Turner syndrome: spectrum, prevalence, and cardiac MRI findings in a pediatric and young adult population. AJR Am J Roentgenol. 2011; 196: 454–460.
Lloyd-Jones D., Leip E. Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 1996; 113: 791–798.
Lopez L., Arheart K., Colan S. et al. Turner syndrome is an independent risk factor for aortic dilation in the young. Pediatrics. 2008; 121: 1622–1627.
Malinowska J., Kolodziejczyk J., Olas B. The disturbance of hemostasis induced by hyperhomocysteinemia; the role of antioxidants. Acta Biochim Pol. 2012; 59((2)): 185–194.
Mavinkurve M., O'Gorman C. Cardiometabolic and vascular risks in young and adolescent girls with Turner syndrome. BBA Clin. 2015; 3: 304–309.
McCully K. Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci. 1993; 23((6)): 477–493.
McCully K. Chemical pathology of homocysteine. III. Cellular function and aging. Ann Clin Lab Sci. 1994; 24((2)): 134–152.
McCully K. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci. 2009; 39((3)): 219–232.
Nahar A., Sabo C., Chitlur M. et al. Plasma homocysteine levels, methylene tetrahydrofolate reductase polymorphisms, and the risk of thromboembolism in children. J Pediatr Hematol Oncol. 2011; 33((5)): 330–333.
Obersby D., Chappell D., Dunnett A., Tsiami A. Plasma total homocysteine status of vegetarians compared with omnivores: a systematic review and meta-analysis. Br J Nutr. 2013; 109((5)): 785–794.
Oliveira K., Verreschi I., Sugawara E. et al. C677T and A1298C polymorphisms of MTHFR gene and their relation to homocysteine levels in Turner syndrome. Genet Test Mol Biomarkers. 2012 May; 16((5)): 396–400.
Oliveira R., Verreschi I., Lipay M. et al. Y chromosome in Turner syndrome: review of the literature. Sao Paulo Med J. 2009; 127: 373–378
Peralta López M., Centeno V., Miras M. et al. Association of vitamin D receptor gene Cdx2 polymorphism with bone markers in Turner syndrome patients. J Pediatr Endocrinol Metab. 2012; 25(7-8): 669-671. doi: 10.1515/jpem-2012-0098.
Peralta López M., Miras M., Silvano L. et al. Vitamin D receptor genotypes are associated with bone mass in patients with Turner syndrome. J Pediatr Endocrinol Metab. 2011 ;24(5-6): 307-312. doi: 10.1515/jpem.2011.047.
Refsum H., Smith A., Ueland P. et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004; 50((1)): 3–32.
Santos L., Laranjeira R., Borborema M. et al. Vitamin D receptor (VDR) gene polymorphisms and expression profile influence upon the immunological imbalance in Turner syndrome. J Endocrinol Invest. 2020; 43(4): 505-513. doi: 10.1007/s40618-019-01135-1.
Steed M. & Tyagi S. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal. 2011; 15: 1927–1943.
Viuff M., Skakkebæk A., Nielsen M. et al. Epigenetics and genomics in Turner syndrome. Am J Med Genet. 2019; 181: 125–132. doi: 10.1002/ajmg.c.31683.
Yang J., Hu X., Zhang Q. et al. Homocysteine level and risk of fracture: A meta-analysis and systematic review. Bone. 2012; 51((3)): 376–382.
Yang R., Pu D., Tan R., Wu J. Association of methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms (C677T and A1298C) with thyroid dysfunction: A meta-analysis and trial sequential analysis. Arch Endocrinol Metab. 2022; 66(4): 551-581. doi: 10.20945/2359-3997000000471.
